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Abstract: Type 2 diabetes is a disorder of dysregulated glucose homeostasis. Normal glucose homeostasis is a complex 
process involving several interacting mechanisms, such as insulin secretion, insulin sensitivity, glucose production, and 
glucose uptake. The dysregulation of one or more of these mechanisms due to environmental and/or genetic factors, can 
lead to a defective glucose homeostasis. Hyperglycemia is managed by augmenting insulin secretion and/or interaction 
with hepatic glucose production, as well as by decreasing dietary caloric intake and raising glucose metabolism through 
exercise. Although these interventions can delay disease progression and correct blood glucose levels, they are not able to 
cure the disease or stop its progression entirely. Better management of type 2 diabetes is sorely needed. Advances in geno-
typing techniques and the availability of large patient cohorts have made it possible to identify common genetic variants 
associated with type 2 diabetes through genome-wide association studies (GWAS). So far, genetic variants on 19 loci 
have been identified. Most of these loci contain or lie close to genes that were not previously linked to diabetes and they 
may thus harbor targets for new drugs. It is also hoped that further genetic studies will pave the way for predictive genetic 
screening. The newly discovered type 2 diabetes genes can be classified based on their presumed molecular function, and 
we discuss the relation between these gene classes and current treatments. We go on to consider whether the new genes 
provide opportunities for developing alternative drug therapies.  
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INTRODUCTION 
  The last few decades have witnessed a dramatic increase 
in the prevalence of type 2 diabetes mellitus, due to changes 
in food intake combined with less physical exercise, a life-
style often referred to as Western. The long-term conse-
quences of type 2 diabetes are severe and include cardiovas-
cular disease, retinopathy, neuropathy, nephropathy, and 
diabetic foot disease. While it has been estimated that world- 
wide around one billion people are obese, over 180 million 
people suffer from type 2 diabetes and this number is ex-
pected to double over the next 25 years. The number of an-
nual deaths due to type 2 diabetes is difficult to estimate be-
cause they are often hidden under cardiovascular disease, but 
the WHO has estimated it to be between 1 and 3 million in 
2006. However, since mortality from this disease often oc-
curs many years after its onset, even 3 million deaths is 
probably an underestimate of the death toll in the near future. 
Although external factors such as food-intake-related obesity 
has attracted much attention, the genetic predisposition for 
diabetes is also important. While the life-time risk for type 2 
diabetes in the Western world is around 10%, first-degree 
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relatives of patients have a 20–40% risk for the disease, and 
concordance rates for identical twins have been estimated to 
be 57% or higher (up to 90%) for type 2 diabetes in male 
twins [1]. The endeavor to find the underlying genes was 
unsuccessful for many years although hundreds of genetic 
associations have been described, based largely on candidate 
genes. Unfortunately, replication was only possible for a 
very few variants. However, the recent advent of genome-
wide association studies (GWAS) holds promise, since such 
studies have now uncovered a number of common genetic 
variants related to diabetes for which replication is also pos-
sible. These genes had not previously been linked to diabetes 
and these loci are therefore expected to lead to new insights 
into the disease mechanisms. 
GLUCOSE HOMEOSTASIS AND DIABETES 
  Diabetes is a state of persistent hyperglycemia, leading to 
irreversible damage in a number of tissues, especially the 
retina, the kidney glomeruli, neural tissue and blood vessels. 
Normally plasma glucose levels are kept within a narrow 
range, a process referred to as glucose homeostasis. This 
homeostasis is regulated in a complex way and involves sev-
eral axes.  
  After eating a meal, a person’s plasma glucose rises tem-
porarily, after which glucose is rapidly taken up by liver and 
muscle and to a lesser degree by fat tissue, due to the effects  
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of insulin released from the pancreatic -cells. Under these 
circumstances, glucose is converted into glycogen, which is 
then stored in the liver. When plasma glucose levels have 
dropped, insulin secretion gradually diminishes. In the post-
prandial state, a minimum level of plasma glucose is assured 
by glucose production in the liver, partly due to release from 
glycogen and partly due to new formation from precursors 
such as lactate and the amino acids alanine and glutamine. 
Insulin has a number of other effects, including lipid storage 
in adipocytes, and it even increases DNA replication and 
protein synthesis. The regulation of insulin release is com-
plex; apart from the prevailing plasma glucose level, release 
from various peptides from the intestine (e.g., glucagon-like 
peptide 1, GLP1) after a meal and feedback mechanisms 
ensure adequate insulin release.  
  Type 2 diabetes is characterized by the combination of 
disturbances in insulin secretion, and an impairment of the 
effects of insulin, so-called insulin resistance, which is often 
related to obesity. Insulin resistance is caused by defects in 
the signaling pathways that process the insulin signal in its 
target tissues. It has often been stated that the disease starts 
with insulin resistance accompanied by raised insulin and 
glucose levels. At a later stage, we presume -cells undergo 
further damage and apoptosis, and are not able to keep up 
with the demand for insulin release, which then results in 
higher glucose levels. At least one of the pathways involved 
in insulin secretion, -cell regeneration, -cell survival, or -
cell development are important in determining the vulner-
ability of the -cell pool in insulin-resistant conditions. Stud-
ies have shown decreases in -cell function prior to the aug-
mentation of plasma glucose in normal glucose-tolerant first-
degree relatives of type 2 diabetes subjects; in these studies 
these relatives had normal insulin sensitivity [2, 3]. While 
obesity is a major risk factor for diabetes – around 50% of 
obese subjects will develop type 2 diabetes at some stage 
(depending on the age when they became obesity) –, it 
should be noted that 20% of type 2 diabetes subjects are not 
obese. It thus seems that obesity is a major risk factor for 
developing type 2 diabetes, but that it is the vulnerability of 
the  -cell pool which determines whether obesity in fact 
triggers type 2 diabetes. 
GENETICS OF TYPE 2 DIABETES 
  Although monogenic forms of diabetes have been found 
(Table 1) (reviewed in [4]), the majority of cases of type 2 
diabetes do not show inheritance as a Mendelian trait, but 
rather as a genetically complex disorder in which genetic 
variants predispose individuals to develop the disease. Twin 
studies have revealed concordance rates of over 50 % (and 
reported up to 90%) for type 2 diabetes in identical twins [1], 
which still leaves a substantial role for environmental fac-
tors, such as excess food and limited physical activity. The 
rapid rise in diabetes prevalence over the last few decades 
strongly suggests that genetic variants involved in type 2 
diabetes are interacting with environmental factors.  
Candidate-Based Association Studies  
  Several candidate gene association studies have been 
performed to identify genes involved in type 2 diabetes. 
These studies test some of the genetic variants in a gene that 
is a strong candidate for being involved in the disease. Al-
though a few genes have been identified in this way, in gen-
eral these studies have not been very successful because the 
results could not be replicated and the p-values for associa-
tion of the genetic variants were moderate.  
  Obviously, the few diabetes genes that were identified 
and replicated in candidate-based association studies had 
already been linked to a diabetic phenotype, since the tested 
genes were mainly selected on the basis of their function and 
their potential relationship with diabetes. The genes identi-
fied by candidate gene approaches were found to be involved 
in rare, monogenic forms of diabetes. The TCF2 gene was 
linked to maturity-onset diabetes of the young (MODY) 5 
[5], while WFS1 gene mutations led to Wolfram (or DID-
MOAD) syndrome, a rare, lethal, neurodegenerative disorder 
that includes diabetes insipidus, diabetes mellitus, optic 
nerve degeneration, and inner ear deafness [6]. The KCNJ11 
gene is related to permanent neonatal diabetes mellitus 
(PNDM), a rare form of diabetes starting before the age of 6 
months [7]. Finally, mutations in PPAR can lead to insulin 
resistance, hypertension, and lipodystrophy [8]. Although the 
molecular impact of mutations in these genes is not yet fully 
understood, it is likely that mutations in them will have dif-
fering effects and that mutations involved in type 2 diabetes 
will have a milder impact on human physiology than those 
involved in monogenic diabetes. 
Genome-Wide Association Studies (GWAS) 
  Recent advances in genotyping techniques and the collec-
tion of large, type 2 diabetes patient cohorts have made it 
possible to perform hypothesis-free genome-wide associa-
tion studies (GWAS) to identify common genetic variants 
that increase susceptibility to type 2 diabetes. The human 
genome harbors around 3 billion base-pairs, which contain at 
least 3 million common single nucleotide polymorphisms 
(SNPs) according to the International HapMap Project. 
However, alleles represented by SNPs that are close together 
have often stayed on the same chromosome in further gen-
erations, forming a so-called haplotype. This implies that 
when one variant has been typed, we know the genotype of a 
set of other variants that surround the initial genetic marker; 
in genetic terminology it is said that the SNPs that stayed 
together on a chromosome are in high linkage disequilib-
rium. It has been estimated that, in a Caucasian population, 
assessing 500,000 SNPs will detect around 80% of the com-
mon genetic variation. GWAS typically involve the assess-
ment of such numbers of SNPs determined in large case-
control studies for association with a disease or with a so-
called “phenotypic trait”, i.e., type 2 diabetes. It should be 
noted that GWAS identify association of a genetic locus, and 
not directly of a gene. It is likely that the most associated 
SNPs in a genomic region are not the causal variant, but that 
the disease-producing SNP is in high linkage disequilibrium 
with the “associated” SNPs. It is also possible that a SNP, 
even when located in a gene, can influence the expression of 
a nearby gene located several thousand base-pairs or more 
away [9]. It is therefore difficult to determine which gene is 
responsible for the association signal in a GWAS with full 
certainty. A detailed description of a GWAS is reviewed by 
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Table 1.  Genes Associated with Diabetes: Overview of their Target Tissue
1, Function
2, and Related Medication
3 
Diabetes  
Gene 
Proposed Diabetes  
Target Cell  
Type / Tissue
1 
Monogenic 
Diabetes
4 
Type 2  
Diabetes
5 
Proposed Function(s) for Gene Product
2 
Drug(s) Affecting the  
Same Pathway as the  
Diabetes Gene
3 
ABCC8 Pancreas  -Cell X   
-  B-cell ion homeostasis and insulin secretion; ATP-
binding cassette transporter that modulates ATP-
sensitive potassium channels and insulin release 
Sulfonylurea derivatives 
ADAMTS9 Unknown  X  -  Cleavage of proteoglycans  Unknown 
CDC123 Pancreas  -Cell   X  -  Cell cycle regulation  Unknown 
CDKAL1 Pancreas  -Cell   X 
-  Growth and development 
-  Proinsulin to insulin conversion 
Unknown 
CDKN2A Pancreas  -Cell   X  -  Cell cycle regulation  Unknown 
CEL Unknown  X   
-  Glycoprotein that is important in regulation of choles-
terol metabolism 
Unknown 
FTO Hypothalamus    X  -  Associated to obesity  Unknown 
GCK Unknown  X   
-  Catalyzes reaction from glucose to glucose-6-
phosphate 
Unknown 
HHEX Pancreas  -Cell   X  -  Growth and development; transcription factor  Unknown 
HNF4 Pancreas  -Cell X    -  Growth and development; transcription factor  Unknown 
IDE Pancreas  -Cell   X  -  Termination of the response to insulin  Unknown 
IGF2BP2 Pancreas  -Cell   X  -  Growth and development  Unknown 
JAZF1 Pancreas  -Cell   X  -  Cell cycle regulation; transcriptional repressor  Unknown 
KCNJ11 Pancreas  -Cell X  X  -  B-cell ion homeostasis and insulin secretion   Sulfonylurea derivatives 
KCNQ1 Pancreas  -Cell   X  -  B-cell ion homeostasis and insulin secretion  Sulfonylurea derivatives 
KLF11 Unknown  X    -  Unknown Unknown 
NEUROD1 Pancreas  -Cell X   
-  Growth and development; transcription factor that 
activates several genes including insulin and is impor-
tant for early -cell development  
Unknown 
NOTCH2 Pancreas  -Cell   X 
-  Growth and development; transcription factor; recep-
tor for membrane bound ligands  
Unknown 
PDX1 Pancreas  -Cell X   
-  Growth and development; nuclear protein that acts as 
a transcriptional activator of several genes including 
insulin and is important for early -cell development  
Unknown 
PPARG Adipocyte    X 
-  Nuclear receptor (transcription factor) that regulates 
adipocyte differentiation 
Thiazolidinediones 
SLC30A8 Pancreas  -Cell   X 
-  B-cell ion homeostasis and insulin secretion; cellular 
efflux of Zn2+ ions 
-  Proinsulin to insulin conversion 
Sulfonylurea derivatives 
TCF1 Pancreas  -Cell X   
-  Growth and development; Transcription factor that 
forms a complex with the product of TCF2 important 
for Wnt signaling 
Unknown 
TCF2 Pancreas  -Cell X  X 
-  Growth and development; transcription factor that 
forms a complex with the product of TCF1 important 
for Wnt signaling 
-  Cell cycle regulation 
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(Table 1) contd…. 
Diabetes  
Gene 
Proposed Diabetes  
Target Cell  
Type / Tissue
1 
Monogenic 
Diabetes
4 
Type 2  
Diabetes
5 
Proposed Function(s) for Gene Product
2 
Drug(s) Affecting the  
Same Pathway as the  
Diabetes Gene
3 
TCF7L2 Pancreas  -Cell   X 
-  Wnt signaling 
-  Proinsulin to insulin conversion 
Unknown 
THADA Pancreas  -Cell   X  -  Apoptosis   Unknown 
TSPAN8 Unknown    X 
-  Glycoprotein involved in the mediation of signal 
transduction  
Unknown 
WFS1 Pancreas  -Cell X  X 
-  Apoptosis; Endoplasmic Reticulum stress pathway 
activation 
Unknown 
Genes included in the list are involved in type 2 diabetes, Maturity Onset Diabetes of the Young (MODY), or Permanent Neonatal Diabetes Mellitus (PNDM). The cut-off p-value for 
the inclusion of type 2 diabetes genes identified by GWAS is 1 x 10
-8 [12, 21-23]. The third and fourth columns of the table show whether a gene is involved in monogenic
4 or com-
plexly inherited type 2 diabetes
5. 
 
  The genome-wide approach has been very successful for 
type 2 diabetes, leading to the identification of over a dozen 
common genetic variants associated with the disease lying 
near genes that had not previously been associated with a 
diabetic phenotype (Table 1) [11-24]. In the near future this 
number will probably increase and a large part of the genetic 
variation that confers susceptibility to type 2 diabetes will be 
unveiled. At present, the total effect of the identified genetic 
variants explains only a small part of the total estimated ge-
netic variation which is mainly due to the small effect from 
each of the identified variants (with odds ratios around 1.2 
for each gene, which implies a mere 20% extra risk for the 
disease) [25, 26]. Identifying more genetic variants - by in-
cluding more cases to increase the statistical power of 
GWAS, performing GWAS in non-Caucasian populations, 
improving the genomic coverage of the GWAS, and per-
forming meta-analyses of the studies published so far - could 
overcome these problems. Moreover, thorough analysis of 
the associated region by deep sequencing could lead to vari-
ants with higher odds ratios being identified (see section 5).  
Functions of Type 2 Diabetes Genes 
  As discussed above, type 2 diabetes is a disease charac-
terized by impaired -cell secretion of insulin, in combina-
tion with resistance to insulin in its target tissues. Both insu-
lin secretion and insulin sensitivity are influenced by genetic 
and environmental factors [27]. Genes that harbor variants 
associated with diabetes can thus be expected to exert their 
effect through one of these pathways.  
  Most genes that play a role in monogenic diabetes are 
important for pancreatic -cell growth and/or function (Table 
1). Genetic variants in three (KCNJ11, TCF2, WFS1) out of 
four replicated genes for type 2 diabetes found by candidate-
based genetic association studies are also related to de-
creased  -cell function. The best characterized gene is 
KCNJ11 which encodes a member of a -cell potassium 
channel involved in insulin secretion [28]. Mutations in 
TCF2 are associated with insulin secretion [29], while 
knock-out mutations in WFS1 have been found to lead to 
Endoplasmic Reticulum (ER) stress and subsequent apopto-
sis of pancreatic -cells [30]. The protein product of the 
fourth gene identified by a candidate gene approach, PPAR, 
is involved in adipocyte differentiation and function (re-
viewed in [31]). Since rare mutations in this gene lead to 
insulin resistance and lipodystrophy, variations in this gene 
are likely to contribute to type 2 diabetes susceptibility 
through altered insulin effects in adipose tissue. 
  To explore the functions of the newly discovered genes, 
various studies have investigated their roles in determining 
sub-phenotypes of type 2 diabetes, such as peripheral insulin 
sensitivity and -cell insulin secretion, and the genetic vari-
ants identified in GWAS (except KCNQ1 because variants in 
this gene have only recently been identified) [32-36]. In gen-
eral, these studies indicate that the genetic variants in the 
genes identified by association studies act through interfer-
ence with insulin secretion and not with peripheral insulin 
sensitivity, and are thus similar to the genes identified 
through candidate gene approaches and in monogenic diabe-
tes. However, insulin secretion and insulin sensitivity are 
related through complex and poorly understood mechanisms. 
Expression studies have revealed that most of the newly dis-
covered type 2 diabetes genes are expressed in multiple cell 
types throughout the body and that the expression of some of 
these genes under diabetic conditions is unaltered in the pan-
creatic islets whereas it is different in other tissues (reviewed 
in [37]). Functional studies of the molecular mechanisms by 
which most genetic variants lead to impaired insulin secre-
tion and the use of animal models have not yet been pub-
lished but are sorely needed.  
  Since only a small percentage of the variability of the 
genetic influence on diabetes risk has been uncovered so far, 
it is still possible that there are mutations in genes that affect 
other axes of the underlying mechanisms of diabetes. It has 
been proposed that multiple hits in several diabetes pathways 
generally occur in subjects destined to develop type 2 diabe-
tes, and that disturbances in -cell function are ultimately 
decisive for the actual development of the hyperglycemic 
state.  
Genetic Subgroups  
  It can be proposed that some of the diabetes genes can be 
grouped into four subgroups based on what is known about 
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ABCC8, and SLC30A8 gene products are involved in cellu-
lar ion homeostasis and insulin secretion. A second group of 
genes – TCF7L2, TCF1, TCF2, HHEX / IDE, IGF2BP2, 
CDKAL1, NEUROD1, PDX1, and NOTCH2 – is likely to 
be involved in the growth and development of the pancreas. 
Of this group TCF7L2, TCF1, and TCF2 are important in 
Wnt signaling (reviewed in [38]). A third group is related 
with cell cycle events: JAZF1 and TCF2 have both been as-
sociated with prostate cancer and these genes might play a 
role in the regulation of the cell cycle [39-41]. CDKN2A 
and, presumably, CDC123 also play a role in the cell cycle. 
Finally, THADA and WFS1 are thought to be involved in 
the apoptosis of -cells. Genes involved in the cell cycle and 
apoptosis of -cells might play a role in diabetes by dysregu-
lating the response of -cells when a higher insulin output is 
called for when insulin resistance is present. 
MANAGEMENT OF TYPE 2 DIABETES AND HOW 
IT IS RELATED TO GENETICS 
  The corner stone for diabetes management still lies in 
diet and exercise [42, 43]. There is also a slowly expanding 
list of drugs being used to treat type 2 diabetes, all of which 
act through one of the pathways important in diabetes patho-
physiology. However, neither changes in lifestyle nor the use 
of medication are sufficient to cure diabetes, although both 
interventions can delay the progression of disease. There is 
therefore an urgent need to develop new medications or 
strategies to counter the huge increase in cases expected in 
the future. Since the management of type 2 diabetes with 
either lifestyle changes, medication or both, is more effective 
when started at an early stage, improving the techniques for 
early diagnosis and the opportunities for early intervention 
will greatly improve the effects of current ways of managing 
type 2 diabetes. 
  Pathways important for the function, growth and devel-
opment of pancreatic -cells provide obvious drug targets 
and are already being used, since defects in insulin secretion 
play a central role in diabetes. Sulfonylurea derivatives are 
widely used and act through improving -cell function by 
closing  -cell potassium channels and thereby enhancing 
insulin secretion. Some of the genes associated with both 
monogenic (ABCC8 and KCNJ11) and complex diabetes 
(KCNJ11, KCNQ1) encode subunits of these potassium 
channels and accordingly, monogenic diabetes of this type 
can be well managed with sulfonylureas. SLC30A8 encodes 
a zinc transporter protein in the -cell and the function of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Classification of diabetes genes with a potential role in -cell function. 
Diabetes genes involved in either type 2 diabetes, Maturity Onset Diabetes of the Young (MODY), or Permanent Neonatal Diabetes Mellitus 
(PNDM) are included. These genes are assigned to pathways and biological process as described in the text. Medications as shown are 
known to affect a subset of -cell functions. Type 2 Diabetes Mellitus  Current Genomics, 2009, Vol. 10, No. 2    115 
this gene product might be related to that of the potassium 
channel genes by regulating ion homeostasis in the -cell 
[44]. 
  The actions of various other drugs involve provoking 
different effects rather than augmenting insulin secretory 
function: thiazolidinediones enhance insulin activity by act-
ing on adipose tissue, metformin lowers hepatic glucose out-
put, and pramlintidine delays gastric emptying and inhibits 
the release of glucagons. GLP1 receptor-agonists or DPP-4 
inhibitors have combined actions on food intake by regulat-
ing satiety and enhancing insulin secretion in the short term, 
and -cell neogenesis and proliferation in the long term (re-
viewed in [45]). The exact physiological mechanisms that 
underlie these improvements are, however, unclear. Except 
for PPAR and genes involved in pancreas growth and sur-
vival, there is no evidence that any of the other genes identi-
fied by GWAS are involved in any of these processes. The 
protein product of PPAR is likely to be involved in the 
mechanism targeted by thiazolidinediones because these 
compounds are ligands of PPAR receptors [46]. Although it 
seems likely that some of the newly discovered diabetes 
genes act in a pathway that is targeted by GLP1 receptor-
agonists or DPP-4 inhibitors, more research into both the 
mechanisms of the medication and the function of the genes 
is needed. 
IMPLICATIONS FOR PREVENTION AND TREAT-
MENT 
Genetic Screening for Prediction and Prevention 
  The effectiveness of current type 2 diabetes management 
is greatly improved when it is started at an early stage of the 
disease. If genetic testing could be used to predict type 2 
diabetes, preventive measures could be taken and diabetes 
could potentially be managed more easily. However, the 
variants associated with type 2 diabetes that have been iden-
tified so far only explain a small percentage of the total ge-
netic variation that is thought to be present [25, 26]. It is 
therefore not yet possible to perform accurate predictive ge-
netic testing but, in the near future, research should provide 
more insight into the opportunities for such testing. Firstly, it 
is expected that many more common genetic variants will be 
identified by performing GWAS in other populations and by 
improving their power and genomic coverage (i.e., more 
patients included in studies and more SNPs tested). Sec-
ondly, performing thorough analyses of the genomic regions 
that show association to the disease by resequencing large 
numbers of patients and controls may identify genetic vari-
ants that have higher odds ratios than the common genetic 
variants identified so far. In a GWAS it is unlikely that the 
functional variant will be identified, but rather one or more 
common variants to which the disease variant is in linkage 
disequilibrium, i.e., that the actual causative mutation(s) is in 
close vicinity to the tested variant. If the frequency of the 
causal disease variant is lower than the tested common SNP, 
we can expect the odds ratio of the causal SNP to be higher 
and this would make the causal SNP a better candidate to use 
for genetic testing. One drawback of genetic testing is that 
many variants have to be tested for each subject, which is 
laborious and costly at present, but improved genotyping and 
resequencing technologies will make screening for such 
variants feasible in the near future.  
New Opportunities for Intervention 
  Even if the exact functions of the majority of the genes 
associated with type 2 diabetes are still elusive, they can be 
broadly grouped into several classes (see Fig. 1). When cer-
tain genes are involved in the same molecular pathway or 
physiological process, not only these genes but the entire 
pathway or process would be an obvious target for new anti-
diabetes drugs. In combination with genetic screening, such 
information could be used to optimize diabetes management 
by prescribing drugs that act on those pathways that are af-
fected in a patient, and vice versa, it is also possible that al-
tering the activity, be it stimulation or inhibition, of undis-
turbed processes could improve glucose homeostasis in se-
lected patients. Improved drug treatment in diabetes can be 
seen in the current management of various MODY subtypes. 
As described above, mutations in genes involved in -cell 
signaling and/or growth in the pancreas have been found to 
be responsible for MODY subtypes. After these mutations 
were identified, the management of these diseases was 
greatly improved by the use of sulfonylurea derivatives, 
which enhances insulin secretion instead of exogenous insu-
lin [44]. The good response of MODY patients to sulfony-
lurea treatment serves as an excellent example of personal-
ized therapy based on genetic screening.  
  Evidence that genes identified by GWAS can represent 
targets for managing type 2 diabetes is provided by the asso-
ciation to this disease of variants in the KCNQ1 and 
KCNJ11 genes. Both these genes encode proteins that are 
members of -cell potassium channels important for insulin 
secretion and these channels are targeted by sulfonylurea 
derivates which are already widely used anti-diabetic drugs 
[44].  
  Another gene, found through a candidate-based associa-
tion study and likely to act in the pathway targeted by thia-
zolidinediones, is PPAR. On the physiological level no rela-
tionships are known between current medications and all the 
other genetic variants identified in either GWAS or candi-
date gene association studies. Therefore all these genes rep-
resent new potential targets for intervention.  
  Type 2 diabetes genes that are presumed to play a role in 
cell cycle regulation (JAZF1, CDKN2A, and CDC123), 
apoptosis (THADA and WFS1), or pancreas development 
and growth (TCF7L2, TCF2, HHEX / IDE, IGF2BP2, 
CDKAL1, and NOTCH2) have not yet been studied well 
enough to predict whether interference with their products 
could be used in managing diabetes. Studies are needed in 
order to better classify these genes.  
  Common variants in type 2 diabetes genes relating to cell 
cycle events and apoptosis, and representing different alleles 
than those associated to type 2 diabetes, are also associated 
with various cancers. In addition, the risks of developing 
diabetes and prostate cancer are correlated in a complex way: 
overall diabetes risk and prostate cancer risk are inversely 
correlated, but while diabetes risk and the risk of developing 
aggressive prostate cancer show no correlation, these two 
risks are positively correlated in lean men and in men who 
undertake vigorous physical activity [47]. Systemic admini-
stration of agents interfering with the gene products of diabe-
tes genes that are also associated with cancers could, there-116    Current Genomics, 2009, Vol. 10, No. 2  Wolfs et al. 
fore, be beneficial in treating diabetes, but they might be 
potentially carcinogenic. Tissue-specific drug targeting or 
additive medication to overcome the carcinogenic side-
effects of such medication needs to be developed to over-
come this problem. Hence, cell-cycle related genes are 
probably not the most promising targets for developing new 
diabetes treatments, unless cell-type-specific targeting of 
drugs becomes a reality. 
  Although the genes containing variants associated with 
type 2 diabetes that seem to be involved in pancreatic growth 
and development have not been well studied yet, we can 
speculate on several possibilities for intervention with such 
genes. Because most genes in this category are not associ-
ated with other diseases, they represent promising interven-
tion targets. Variants in these genes might affect the regen-
erative or proliferative potential of the -cell population 
when there is an increased demand for insulin secretion. In 
this case it would be possible to use such genes, or the mo-
lecular pathways they are involved in, as a target for inter-
vention, in an attempt to correct the poor response of the -
cells and ultimately aiming to improve insulin secretion.  
  Another possibility is that variants in these genes cause 
pancreatic damage, which would lead to endocrine malfunc-
tion of the pancreas at an early stage of the diabetic devel-
opment. The possibilities for therapeutic intervention would 
largely depend on the severity and reversibility of such a 
malfunction.  
  Genetic variants in three genes identified (or confirmed) 
by GWAS (TCF7L2, CDKAL1, and SLC30A8) are associ-
ated with impairment of proinsulin-to-insulin conversion, 
whereas variants in other genes identified by GWAS are not 
associated to this [48]. Even if the affected proinsulin-to-
insulin conversion is not a primary but a secondary effect of 
genetic variants in one of the three genes, reconstituting this 
process would enhance insulin secretion and thereby enhance 
-cell function. Although the conversion of proinsulin-to-
insulin has long been known to be involved in type 2 diabe-
tes [49], the mechanisms that regulate this process are still 
undetermined and there is no current therapy that acts by 
interfering with this process. Association of TCF7L2, 
CDKAL1, and SLC30A8 to impaired proinsulin-to-insulin 
conversion has provided evidence that these genes are some-
how related to this process and this clears the way for func-
tional research and development of new medication.  
CONCLUSIONS 
  GWAS are an important tool for identifying genetic 
variation and they have been very successful in finding 19 
genetic loci involved in type 2 diabetes. Genotyping tech-
niques will continue to improve and patient cohorts will be-
come larger, which will lead to more genetic variants being 
identified in the near future. Although the true causal SNPs 
are often not known, it is anticipated they will be uncovered 
by deep sequencing of the genomic regions containing asso-
ciation signals. These advances will help elucidate a higher 
percentage of the total genetic variation, and improve oppor-
tunities for genetic screening and personalized diabetes care. 
Functional studies and animal models harboring specific 
gene deletions will be needed to study the role of such muta-
tions, while genetic studies using sharply defined endophe-
notypes will greatly enhance our knowledge about the type 2 
diabetes genes identified by GWAS.  
  At present, it is too early to expect results from GWAS to 
lead to new therapies. Nevertheless, it is clear that genetic 
studies are crucial to dissecting the mechanisms underlying 
the biological processes and to finding ways to intervene 
with them, as they provide important clues for directing the 
focus of functional research. The ongoing avalanche of ge-
netic information about type 2 diabetes will thus pave the 
way to further research in the field and has already yielded 
important information to aid the development of new thera-
peutic strategies. 
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